Influx Healthtech Ltd.

Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.
Contact No. : +91 9820201063 / 8080333319 / 8411879521
Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com
Website : www.influxhealthcare.com
CIN : L24299MH2020PLC346825

November 4, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code – INFLUX

Dear Sir/Ma'am,

Sub.: Outcome of Board Meeting.
Ref.: Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform that the Board of Directors of Influx Healthtech Limited at its meeting held today i.e., **Wednesday, November 4, 2026** has inter-alia considered and approved/noted the following matters:

1) Consideration and Approval of the Financial Results:

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") as amended, we forward herewith the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Reports of the Company for the Six Months and Half-year ended September 30, 2026, which were approved and taken on record by the Board of Directors of the Company at its meeting held today.

The said results will also available on the Company's website at www.influxhealthtech.com.

2) Taken note of Certificate of Utilization of Issue Proceeds certified by Statutory Auditor for the half year ended September 30, 2026.

In terms of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with applicable SEBI Circulars, the Board of Directors of the Company has taken note of the Certificate of Utilization of Issue Proceeds for the half year ended September 30, 2026, certified by the Statutory Auditor of the Company. The said certificate is enclosed herewith for your information and record.

3) Taken note of the order issued by the National Stock Exchange of India Limited (NSE) regarding rejection of the waiver application and payment of fine:

The Board of Directors took note of the NSE order dated September 23, 2026, rejecting the Company's waiver application for the fine imposed under Regulation 33 of the Listing Regulations and noted that the total fine of ₹1,82,900/-, inclusive of GST, was duly paid on October 1, 2026.

Influx Healthtech Ltd.

Regd. Office : 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory : Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404. Maharashtra.
Contact No. : +91 9820201063 / 8080333319 / 8411879521
Email : influxhealthtech@gmail.com/ influxhealthcare1@gmail.com
Website : www.influxhealthcare.com
CIN : L24299MH2020PLC346825

The above matter has been duly approved by the Board of Directors at their meeting which commenced at 1:00 PM and concluded at 3:15 PM.

The same will be made available on the Company's website.

We request you to take the above information on record.

Thanking you,

For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala

Digitally signed by Munir Abdul Ganee Chandniwala
Date: 2026.11.04 15:23:51 +05'30'

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

V. B. Goel & Co
Chartered Accountants

Simba Tower, 6th Floor,
Vishveshwar Nagar,
Goregaon (East), Mumbai – 400 063
✆ +91 22 28441350/35174263/46030191
✉ info@vbgco.com
Website: www.vbgco.com

Independent Auditor's Limited Review Report on unaudited standalone financial results of Influx Healthtech Limited for the half year ended September 30, 2026 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Influx Healthtech Limited

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results ('the Statement') of **INFLUX HEALTHTECH LIMITED** ("the Company") for the half year ended September 30, 2026 for the period from April 01, 2026 to September 30, 2026 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations"), including the relevant circulars issued by SEBI from time to time. We have initialed the Statement for identification purposes only.

This statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Accounting Standard 25, Interim Financial Reporting, specified under Section 133 of the Companies Act 2013, read with relevant rules issued thereunder, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our Responsibility is to express a conclusion on the Statement based on our review of the Statement.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "*Review Interim Financial Information performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of Interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted and procedures performed as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards, specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

The Figures for the half year ended March 31, 2026 are the balancing figures between Audited Figures in respect of the full financial year and the year to date figures upto the half year ended September 30, 2025, which were subjected to limited review by us. Our opinion on the Statement is not modified in respect of this matter.

FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

V. B. GOEL & CO. MUMBAI 63. CHARTERED ACCOUNTANTS

(Vikas Goel)
Partner
Membership No: 039287
UDIN: 26039287KZCPNM2951

Place: Mumbai
Date: 04/11/2026

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

STATEMENT OF UNAUDITED/AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

Sr. No.	Particulars	Half Year Ended			For the year Ended
		30.09.2026	31.03.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Audited
1	**Income**				
a.	Revenue from Operations	8,541.45	8,006.90	6,676.46	14,683.36
b.	Other Income	33.63	124.03	9.46	133.49
	Total Income	**8,575.08**	**8,130.93**	**6,685.92**	**14,816.85**
2	**Expenses**				
a.	Cost of Material Consumed	5,356.10	5,012.23	3,909.49	8,921.72
b.	Changes in inventories of Finished Goods	(274.82)	(97.06)	(155.55)	(252.61)
c.	Employee Benefit Expenses	656.74	666.53	508.94	1,175.47
d.	Finance Cost	13.51	18.32	0.10	18.42
e.	Depreciation & Amortization	233.88	209.47	168.33	377.80
f.	Other Expenses	968.42	905.28	947.38	1,852.65
	Total Expenses	**6,953.83**	**6,714.76**	**5,378.69**	**12,093.45**
3	**Total Profit/(Loss) Before Exceptional Items and Tax**	**1,621.25**	**1,416.17**	**1,307.24**	**2,723.40**
4	Exceptional Items	-	-	-	-
5	**Total Profit / (Loss) Before Tax**	**1,621.25**	**1,416.17**	**1,307.24**	**2,723.40**
6	**Tax Expense**				
a.	Current Tax	351.34	365.09	345.38	710.47
b.	Deferred Tax	(10.05)	(3.51)	(39.42)	(42.93)
c.	Short/(Excess) Provision for Earlier years	75.72	-	-	1.73
7	**Total Tax Expenses**	**417.01**	**361.58**	**305.96**	**669.27**
8	**Net Profit/(Loss) for a period (5-7)**	**1,204.24**	**1,054.59**	**1,001.28**	**2,054.13**
9	Profit/(Loss) for The Period from discontinued operations before tax	-	-	-	-
10	Tax Expense of discontinued operations	-	-	-	-
11	**Net Profit/(Loss) from discontinued operation after tax (9-10)**	-	-	-	-
12	**Net Profit/(Loss) for the year**	**1,204.24**	**1,054.59**	**1,001.28**	**2,054.13**
	Paid up Equity Share Capital (Face value of Rs. 10/ each)	2,315.04	2,315.04	2,315.04	2,315.04
13	**Earnings per share**				
	a. Basic (in Rs.)	5.20	4.56	4.81	9.35
	b. Diluted (in Rs.)	5.20	4.56	4.81	9.35

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M.A. Chandniwal.

Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 04/11/2026

V. B. GOEL & CO. MUMBAI 63. CHARTERED ACCOUNTANTS

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON SEPTEMBER 30, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

Particulars	As at 30-09-2026 Unaudited	As at 31-03-2026 Audited
I EQUITY AND LIABILITIES		
(1) Shareholders' fund		
Share Capital	2,315.04	2,315.04
Reserves and Surplus	8,965.18	7,760.93
Total Shareholders Fund	**11,280.22**	**10,075.97**
(2) Non-Current Liabilities		
Other Long Term Liabilities	2.00	-
Long Term Provisions	40.09	23.43
Total Non-Current Liabilities	**42.09**	**23.43**
(3) Current Liabilities		
Trade Payables	2,412.33	1,912.11
Other Current Liabilities	337.46	305.73
Short Term Provisions	-	53.17
Total Current Liabilities	**2,749.79**	**2,271.01**
Total Equity and Liabilities	**14,072.10**	**12,370.41**
II ASSETS		
(1) Non-Current Assets		
(i) Property Plant & Equipment and Intangible Assets		
Property Plant & Equipment	3,427.87	2,755.22
Intangible Assets	13.78	2.83
Capital work-in-progress	1,478.12	346.91
Intangible Assets under development	3.90	1.69
Total Property, Plant & Equipments	**4,923.67**	**3,106.64**
(ii) Non-Current Investments	1.00	1.00
(iii) Deffered tax assets (net)	71.23	61.17
(iv) Long-term loans and advances	774.50	919.01
(v) Other non-current assets	145.97	137.10
Total Non-Current Assets	**5,916.37**	**4,224.92**
(2) Current Assets		
Current Investments	549.97	229.99
Inventories	2,340.81	1,593.27
Trade Receivables	3,387.39	3,378.04
Cash & Cash Equivalents	959.58	2,515.74
Short-term loans and advances	896.02	393.49
Other current assets	21.96	34.95
Total Current Assets	**8,155.74**	**8,145.48**
TOTAL ASSETS	**14,072.10**	**12,370.41**

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M.A. Chandniwala

Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 04/11/2026

V. B. GOEL & CO. CHARTERED ACCOUNTANTS MUMBAI 63

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

STANDALONE STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

Sl.	Particulars	For the year ended 30.09.2026	For the year ended 31.03.2026
		Unaudited	Audited
A)	**Cash Flow from Operating Activities**		
	Net Profit before tax & extraordinary items	1,621.27	2,723.40
	Adjustment For :		
	Depreciation & Amortization Expenses	233.88	377.80
	Bad Debts Written Off	0.70	36.09
	Provision for bad and doubtful debts	23.75	10.24
	Interest Expenses & other finance cost	13.51	18.42
	Interest Income	(31.33)	(16.66)
	Charges in investments	0.02	-
	Loss on variation in foreign exchange rate	2.67	-
	Income from investments	-	(112.47)
	Operating Profit Before Working Capital Changes	1,864.47	3,036.82
	Adjusted for :		
	Increase/(Decrease) in Trade payables	500.22	(1,029.85)
	Increase/(Decrease) in Other Current Liabilities	39.52	26.56
	Increase/(Decrease) in Other Non-current Liabilities	2.00	(5.26)
	Increase/(Decrease) in Provision	16.66	5.70
	(Increase)/Decrease in Trade Receivables	(36.47)	(180.27)
	(Increase)/Decrease in Inventories	(747.54)	(271.54)
	(Increase)/Decrease in Loans and Advances	(308.93)	(316.93)
	(Increase)/Decrease in Other Current and Non-current Assets	(3.78)	(41.45)
	Net Cash generated from Operating activities (before tax)	1,326.15	1,223.78
	(Tax Paid)/ Tax Refund - Net	(597.13)	(834.92)
	Net Cash Generated from Operating Activities (A)	729.02	388.86
B)	Cash Flow from Investing Activities		
	Purchase of Property, Plant and Equipment, Capital Work in Progress, Intangible Assets and Intangible Assets under development	(1,914.19)	(2,456.19)
	Cash Outflow from Investments in securities	(336.87)	(118.52)
	Inter-corporate Loan	(73.34)	-
	Maturity of fixed deposit	-	50.00
	Interest Income	39.23	7.70
	Net Cash used in Investment Activities (B)	(2,285.17)	(2,517.01)
C)	**Cash Flow from Financing Activities**		
	Proceeds from Initial Public Offer (net of issue expenses)	-	4,474.75
	(Repayment)/ Proceeds of Short Term Borrowings	-	(21.92)
	Net cash generated from / (used in) Financing Activities (C)	-	4,452.83
	Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(1,556.15)	2,324.68
	Cash and Cash Equivalents at the beginning of the Year		
	Cash and cash equivalents	211.87	191.06
	Short term bank deposits	2,303.87	-
	Cash and cash equivalents at the end of the Year	959.59	2,515.74
	Cash and cash equivalents comprise of:		
	Cash on Hand	4.44	4.69
	Bank Balances:		
	In Current Accounts	339.48	207.18
	Short Term Bank Deposit	615.67	2,303.87
	Cash and cash equivalents at the end of the Year	959.59	2,515.74

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala

Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 04/11/2026

V. B. GOEL & CO. CHARTERED ACCOUNTANTS MUMBAI 63.

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

Notes to standalone financial results for the Half Year Ended 30th September, 2026

1 The above results have been prepared as per Generally Accepted Accounting Principles in India, prescribed u/s section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in accordance with the recognition and measurement principles laid down in Accounting Standard, as applicable, specified in Section 133 of the Companies Act, 2013 read with relevant rules framed thereunder or as specified by the Institute of Chartered Accountants of India, whichever is applicable.

2 The above results for the half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 04th, 2026.

3 The results for the half year ended September 30, 2026 has been reviewed by the Statutory Auditors of the Company, M/s V. B. Goel & Co. Chartered Accountants as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

4 Since there are no separate reportable business segments, the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.

5 The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20.

6 The basic and diluted EPS for the half year ended Sep 30 2026, Mar 31 2026 and Sep 30 2025 are not annualised.

7 Previous period figures have been re-grouped and re-classified wherever necessary.

8 The statement includes the results for the half year ended March 31, 2026 being the balanced figure between audited figures in respect of the full financial year and the published un-audited figures in respect of 1st half year of the previous financial year, which were subject to limited review by the statutory auditors.

9 There were no investor complaints known to the Company outstanding at the beginning and at the half year ended September 30, 2026.

10 As the Company is listed on SME Emerge platform of National Stock Exchange of India Limited, the requirement of submitting "year to date" financial result is not applicable under Regulation 33(5) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

11 The results of the Company are also available for investors at www.influxhealthtech.com

12 The company has completed fresh issue of Equity Shares by Initial Public Offer ("IPO") of 50,00,400 Equity Shares of face value Rs.10 each at an issue price of Rs. 96 per equity share. The Equity Shares of the company were listed on National Stock Exchange of India Limited ("NSE") Emerge Platform on June 25, 2025. The details of utilization of the net proceeds as mentioned below:

V. B. GOEL & CO. MUMBAI 63. CHARTERED ACCOUNTANTS

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

Sr No.	Objects as disclosed in the offer document	Amount disclosed in offer document	Amount utilized upto 30.09.2026	Unutilized amount as on 30.09.2026
1	Funding Capital expenditure requirements for setting up of manufacturing facilities	3,673.34	2,941.17	732.17
2	General Corprate Purpose	667.40	667.40	-
3	Public Issue Expenses	583.24	583.24	-
	Total	**4,923.98**	**4,191.81**	732.17

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M.A. Chandniwal.

Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 04/11/2026

V. B. GOEL & CO. MUMBAI 63. CHARTERED ACCOUNTANTS

V. B. Goel & Co
Chartered Accountants

Simba Tower, 6th Floor,
Vishveshwar Nagar,
Goregaon (East), Mumbai – 400 063
✆ +91 22 28441350/35174263/46030191
✉ info@vbgco.com
Website: www.vbgco.com

Independent Auditor's Limited Review Report on Unaudited Consolidated Financial Results of Influx Healthtech Limited for the half year ended September 30, 2026 pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Influx Healthtech Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results ('the Statement') of **INFLUX HEALTHTECH LIMITED** ("herein referred to as "the Parent Company") and its subsidiaries (the Parent Company and its subsidiaries together referred to as "the Group"), for the half year ended September 30, 2026 (the "Statement") attached herewith, being submitted by the Parent Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations"), including the relevant circulars issued by SEBI from time to time. We have initialed the Statement for identification purpose.

This statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Accounting Standard 25, Interim Financial Reporting, specified under Section 133 of the Companies Act 2013, read with relevant rules issued thereunder, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our Responsibility is to express a conclusion on the Statement based on our review of the Statement.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "*Review Interim Financial Information performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of Interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entity;

Holding Company
Influx Healthtech Limited

Subsidiary
Olahey Wellness Private Limited

Based on our review conducted and procedures performed as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards, specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

The Holding Company acquired the Olahey Wellness Private Limited ("the Subsidiary") in February 2026 and accordingly the Holding Company did not have any subsidiary during the half year ended 30th September 2025. The figures for the corresponding half year ended 30th September 2025 represent the standalone figures of the Holding Company and have been presented solely to comply with the format prescribed under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the figures for the half year ended 30th September 2026 are not comparable with those of the corresponding half year ended 30th September 2025. Our Opinion is not qualified in respect of this matter.

FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

V. B. GOEL & CO. ★ MUMBAI 63. ★ CHARTERED ACCOUNTANTS

(Vikas Goel)
Partner
Membership No: 039287
UDIN: 26039287AEANLX2749

Place: Mumbai
Date: 04/11/2026

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

Sr. No.	Particulars	Half Year Ended			For the year Ended
		30.09.2026	31.03.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Audited
1	**Income**				
a.	Revenue from Operations	8,541.45	8,006.90	6,676.46	14,683.36
b.	Other Income	31.38	124.03	9.46	133.49
	Total Income	**8,572.83**	**8,130.93**	**6,685.92**	**14,816.85**
2	**Expenses**				
a.	Cost of Material Consumed	5,356.10	5,012.23	3,909.49	8,921.72
b.	Changes in inventories of Finished Goods	(274.82)	(97.06)	(155.55)	(252.61)
c.	Employee Benefit Expenses	656.74	666.53	508.94	1,175.47
d.	Finance Cost	13.51	18.32	0.10	18.42
e.	Depreciation & Amortization	233.88	209.47	168.33	377.80
f.	Other Expenses	969.42	905.62	947.38	1,853.00
	Total Expenses	**6,954.82**	**6,715.11**	**5,378.69**	**12,093.80**
3	Total Profit/(Loss) Before Exceptional Items and Tax	**1,618.01**	**1,415.82**	**1,307.23**	**2,723.05**
4	Exceptional Items	-	-	-	-
5	**Total Profit / (Loss) Before Tax**	**1,618.01**	**1,415.82**	**1,307.23**	**2,723.05**
6	**Tax Expense**				
a.	Current Tax	351.34	365.09	345.38	710.47
b.	Deferred Tax	(10.30)	(3.59)	(39.42)	(43.02)
c.	Short/(Excess) Provision for Earlier years	75.72	-	-	1.73
7	**Total Tax Expenses**	**416.76**	**361.49**	**305.96**	**669.18**
8	**Net Profit/(Loss) for a period (5-7)**	**1,201.25**	**1,054.33**	**1,001.27**	**2,053.87**
9	Profit/(Loss) for The Period from discontinued operations before tax	-	-	-	-
10	Tax Expense of discontinued operations	-	-	-	-
11	**Net Profit/(Loss) from discontinued operation after tax (9-10)**	-	-	-	-
12	**Net Profit/(Loss) for the year**	**1,201.25**	**1,054.33**	**1,001.27**	**2,053.87**
	Paid up Equity Share Capital (Face value of Rs. 10/- each)	2,315.04	2,315.04	2,315.04	2,315.04
13	**Earnings per share**				
	a. Basic (in Rs.)	5.19	4.55	4.81	9.35
	b. Diluted (in Rs.)	5.19	4.55	4.81	9.35

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwal

Munir Chandniwala
(Managing Director)
DIN : 08459582

Place: Mumbai
Date: 04/11/2026

V.B. GOEL & CO. CHARTERED ACCOUNTANTS MUMBAI 63

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS ON SEPTEMBER 30, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

Particulars	As at 30-09-2026 Unaudited	As at 31-03-2026 Audited
I EQUITY AND LIABILITIES		
(1) Shareholders' fund		
Share Capital	2,315.04	2,315.04
Reserves and Surplus	8,962.91	7,760.67
Total Shareholders Fund	**11,277.95**	**10,075.71**
(2) Non-Current Liabilities		
Long Term Provisions	40.09	23.43
Total Non-Current Liabilities	**40.09**	**23.43**
(3) Current Liabilities		
Trade Payables	2,422.88	1,912.26
Other Current Liabilities	337.46	305.73
Short Term Provisions	-	53.17
Total Current Liabilities	2,760.34	2,271.16
Total Equity and Liabilities	**14,078.38**	**12,370.30**
II ASSETS		
(1) Non-Current Assets		
(i) Property Plant & Equipment and Intangible Assets		
Property Plant & Equipment	3,427.87	2,755.22
Intangible Assets	13.78	2.83
Capital work-in-progress	1,496.90	346.91
Intangible Assets under development	3.90	1.69
Total Property, Plant & Equipments	**4,942.45**	**3,106.65**
(ii) Deffered tax assets (net)	71.57	61.26
(iii) Long-term loans and advances	829.01	919.01
(iv) Other non-current assets	145.97	137.10
Total Non-Current Assets	**5,989.00**	**4,224.03**
(2) Current Assets		
Current Investments	549.97	229.99
Inventories	2,340.81	1,593.27
Trade Receivables	3,387.39	3,378.04
Cash & Cash Equivalents	964.57	2,516.54
Short-term loans and advances	825.93	393.49
Other current assets	19.71	34.95
Total Current Assets	**8,088.38**	**8,146.28**
TOTAL ASSETS	**14,077.38**	**12,370.30**

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M.A. Chandniwala

Munir Chandniwala
(Managing Director)
DIN : 08459582

Place: Mumbai
Date: 04/11/2026

V. B. GOEL & CO. CHARTERED ACCOUNTANTS MUMBAI 63.

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

CONSOLIDATED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

Sl.	Particulars	For the Half Year Ended 30.09.2026	For the year ended 31.03.2026
		Unaudited	Audited
A)	**Cash Flow from Operating Activities**		
	Net Profit before tax & extraordinary items	1,618.01	2,723.05
	Adjustment For :		
	Depreciation & Amortization Expenses	233.88	377.80
	Bad Debts Written Off	0.70	36.09
	Provision for bad and doubtful debts	23.75	10.24
	Interest Expenses & other finance cost	13.51	18.42
	Interest Income	(31.33)	(16.66)
	Charges in Investments	0.02	-
	Loss on variation in foreign exchange rate	2.67	-
	Income from investments	-	(112.47)
	Operating Profit Before Working Capital Changes	**1,861.20**	**3,036.47**
	Adjusted for :		
	Increase/(Decrease) in Trade payables	510.61	(1,029.70)
	Increase/(Decrease) in Other Current Liabilities	39.52	26.56
	Increase/(Decrease) in Other Non-current Liabilities	-	(5.26)
	Increase/(Decrease) in Provision	16.66	5.70
	(Increase)/Decrease in Trade Receivables	(36.47)	(180.28)
	(Increase)/Decrease in Inventories	(747.54)	(271.54)
	(Increase)/Decrease in Loans and Advances	(329.05)	(316.93)
	(Increase)/Decrease in Other Current and Non-current Assets	(1.53)	(41.45)
	Net Cash generated from Operating activities (before tax)	**1,313.40**	**1,223.57**
	(Tax Paid)/ Tax Refund - Net	(597.13)	(834.92)
	Net Cash Generated from Operating Activities (A)	**716.27**	**388.65**
B)	**Cash Flow from Investing Activities**		
	Purchase of Property, Plant and Equipment, Capital Work in Progress, Intangible Assets and Intangible Assets under development	(1,987.47)	(2,456.19)
	Investment in Securities	(320.00)	(117.52)
	Maturity of fixed deposit	-	50.00
	Interest Income	39.23	7.70
	Net Cash used in Investment Activities (B)	**(2,268.24)**	**(2,516.01)**

V. B. GOEL & CO. CHARTERED ACCOUNTANTS MUMBAI 63.

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

CONSOLIDATED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(All amount in Rs. Lakhs, unless otherwise stated)

Sl.	Particulars	For the Half Year Ended 30.09.2026	For the year ended 31.03.2026
C)	**Cash Flow from Financing Activities**		
	Proceeds from Initial Public Offer (net of issue expenses)	-	4,474.75
	(Repayment)/ Proceeds of Short Term Borrowings	-	(21.92)
	Net cash generated from / (used in) Financing Activities (C)	-	4,452.83
	Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(1,551.97)	2,325.47
	Cash and Cash Equivalents at the beginning of the Year		
	Cash and cash equivalents	212.67	191.06
	Short term bank deposits	2,303.87	-
	Cash and cash equivalents at the end of the Year	964.57	2,516.54
	Cash and cash equivalents comprise of:		
	Cash on Hand	4.44	4.69
	Bank Balances:		
	In Current Accounts	344.47	207.98
	Short Term Bank Deposit	615.66	2,303.87
	Cash and cash equivalents at the end of the Year	964.57	2,516.54

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M. A. Chandniwala.

Munir Chandniwala
(Managing Director)
DIN : 08459582

V. B. GOEL & CO. CHARTERED ACCOUNTANTS MUMBAI 63

Place: Mumbai
Date: 04/11/2026

Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

Notes to consolidated financial results for the Half Year Ended September 30, 2026

1 The consolidated financial results of Parent and its subsidiaries [collectively referred as 'Group'], include the result of the Company and following entities:

Company Name	Consolidated as
Olahey Wellness Private Limited	Subsidiary

2 The above results have been prepared as per Generally Accepted Accounting Principles in India, prescribed u/s section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable and in accordance with the recognition and measurement principles laid down in Accounting Standard, as applicable, specified in Section 133 of the Companies Act, 2013 read with relevant rules framed thereunder or as specified by the Institute of Chartered Accountants of India, whichever is applicable.

3 The above results for the half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on November 04th, 2026.

4 The results for the half year ended September 30, 2026 has been reviewed by the Statutory Auditors of the Company, M/s V. B. Goel & Co. Chartered Accountants as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

5 Since there are no separate reportable business segments, the disclosure requirements as per AS 17 "Segment Reporting" are not applicable.

6 The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20.

7 The results of the Company are also available for investors at www.influxhealthtech.com.

8 The Holding Company acquired the Olahey Wellness Private Limited ("the Subsidiary") in February 2026 and accordingly the Holding Company did not have any subsidiary during the half year ended 30th September 2025. The figures for the corresponding half year ended 30th September 2025 represent the standalone figures of the Company and have been presented solely to comply with the format prescribed under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the figures for the half year ended 30th September 2026 are not comparable with those of the corresponding half year ended 30th September 2025.

9 The Holding company has completed fresh issue of Equity Shares by Initial Public Offer ("IPO") of 50,00,400 Equity Shares of face value Rs.10 each at an issue price of Rs. 96 per equity share. The Equity Shares of the company were listed on National Stock Exchange of India Limited ("NSE") Emerge Platform on June 25, 2025. The details of utilization of the net proceeds as mentioned below:



Influx Healthtech Ltd.

Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.
Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521
Email: influxhealthtech@gmail.com / info@influxhealthtech.com
Website: www.influxhealthtech.co.in
CIN: L24299MH2020PLC346825

Sr No.	Objects as disclosed in the offer document	Amount disclosed in offer document	Amount utilized upto 30.09.2026	Unutilized amount as on 30.09.2026
1	Funding Capital expenditure requirements for setting up of manufacturing facilities	3,673.34	2,941.17	732.17
2	General Corprate Purpose	667.40	667.40	-
3	Public Issue Expenses	583.24	583.24	-
	Total	**4,923.98**	**4,191.81**	**732.17**

For and on the behalf of Board of Directors of
Influx Healthtech Limited

M.A. Chandniwal

Munir Chandniwala
(Managing Director)
DIN : 08459582
Place: Mumbai
Date: 04/11/2026

V. B. GOEL & CO. MUMBAI 63. CHARTERED ACCOUNTANTS

V. B. Goel & Co
Chartered Accountants

Simba Tower, 6th Floor,
Vishveshwar Nagar,
Goregaon (East), Mumbai – 400 063
✆ +91 22 28441350/35174263/46030191
✉ info@vbgco.com
Website: www.vbgco.com

To,
The Board of Directors
Influx Healthtech Limited

We, the statutory auditors of Influx Healthtech Limited having registered office at 109, Ghanshyam Enclave Premises Co-op Soc, Plot No. 856, Laljipada, Kandivali West, Mumbai - 400067 have verified the books of accounts of the Company and other relevant records produced before us. On the basis of such verification and according to information and explanations given to us, we confirm that the company has utilized the following amount from the issue proceeds.

(Rupees in Lakhs)

Sr. No.	Objects as disclosed in the Offer document	Amount disclosed in the Offer document	Actual Utilized Amount upto 30.09.2026	Unutilized Amount as on 30.09.2026
1	Funding Capital expenditure requirements for setting up of manufacturing facilities for Nutraceutical Division	2,865.06*	2,312.68	552.38
2	Funding Capital expenditure requirements for setting up of manufacturing facilities for Veterinary Food Division	599.23*	476.70	122.53
3	Purchase of Machineries for Homecare and Cosmetic Division	209.05*	151.79	57.26
4	General Corporate Purpose	667.40	667.40	-
5	Public Issue Expenses	583.24	583.24	-
Total		**4,923.98**	**4,191.81**	**732.17**

**Amended vide Special Resolution passed through Postal Ballot dated 02nd May, 2026.*

This Certificate is intended for your information or to be provided to any entity or Regulatory Authority in connection with the utilization of issue proceeds and is not to be used, referred to or distributed for any other purpose without our written consent.

FOR V. B. GOEL & CO.
Chartered Accountants
Firm Reg. No. 115906 W

V. B. GOEL & CO. MUMBAI 63. CHARTERED ACCOUNTANTS

(Vikas Goel)
Partner
Membership No: 039287
UDIN: 26039287SYCDEV5501

Place: Mumbai
Date: 04/11/2026